Until we end the FDA’s monopoly on medical decision-making, patients will keep paying the price for politics disguised as protection.
The current system places the fate of countless individuals in the hands of a single regulatory body, often burdened by political influences rather than purely scientific considerations. This monopoly delays access to potentially life-saving treatments and limits patient autonomy.
By diversifying decision-making authority and encouraging competition, we can foster innovation and provide patients with more timely, personalized medical options. It’s time to rethink the status quo and prioritize patient well-being over bureaucratic control.
https://www.cato.org/blog/when-fda-becomes-political-patients-autonomy-suffers
